Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CA4 | P22748 | 1/20 | 0.69 |
| ▸ | CA6 | P23280 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | TTR | P02766 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29524334 | 1.00 | TPMT (0.69) | TPMTCA12CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL11850718 | 0.98 | CA12 (0.67) | TPMTCA12CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL306990 | 0.98 | CA12 (0.67) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL11575925 | 0.86 | CYP1A2 (0.68) | TTRHTTLMNARAB9ATSHR | |
| SCHEMBL9659618 | 0.85 | CES2 (0.53) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL311716 | 0.85 | ADRB2 (0.60) | HTTRAB9AMAPK1TSHRALDH1A1 | |
| SCHEMBL411025 | 0.85 | CA12 (0.69) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL1191273 | 0.85 | TAS1R3 (0.52) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL30446783 | 0.85 | TAS1R3 (0.52) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL15010753 | 0.84 | TTR (0.66) | TPMTCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214921-A1 | METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND | KAO CORPORATION (JP) | 2025-07-03 | — | — | US | claimed |
| EP-4501896-A1 | METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND | Kao Corporation (JP) | 2025-02-05 | — | — | EP | claimed |
| CN-118973990-A | Process for producing cyclic diketone compound | 花王株式会社 | 2024-11-15 | — | — | CN | claimed |
| WO-2023189722-A1 | METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND | 花王株式会社 | 2023-10-05 | — | — | WO | claimed |
| CN-115598271-A | Analysis method of 3, 5-dichloro-4-methoxybenzoic acid | 苏州天马医药集团天吉生物制药有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| EP-3551633-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| WO-2018108230-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | claimed |
| EP-2516479-B1 | NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS | BASF CORP (US) | 2016-04-20 | — | — | EP | claimed |
| EP-4743457-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE | 4M THERAPEUTICS INC. (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122037481-A | Aging-resistant long-acting antibacterial plastic bottle and preparation method thereof | 佛山市恒信功成塑料有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4667461-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON S AND GAUCHER DISEASE | Children's Hospital Medical Center (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | CHILDRENS HOSPITAL MED CT (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2025-08-07 | — | — | US | disclosed |
| EP-0159291-A1 | Ink composition for the ink-jet printing process | CIBA-GEIGY AG (CH) | 1985-10-23 | — | — | EP | disclosed |
| US-4315766-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | disclosed |
| EP-0017931-A2 | 4H-3,1-Benzoxazine derivatives, methods of their preparation and their use in combating undesirable vegetation | BASF Aktiengesellschaft (DE) | 1980-10-29 | — | — | EP | disclosed |
| US-4009208-A | N,N'-HEPTAMETHYLENEBIS(4-METHOXYBENZAMIDE) | STERLING DRUG INC. (US) | 1977-02-22 | — | — | US | disclosed |
| US-3975537-A | SUBSTITUTED BENZOFURANS | SMITH KLINE (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | TPMT 2954/4885CA12 4700/4885CA1 2594/4885 |
| US-20250214921-A1 | METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND | HSD17B7, HSD17B12, BCKDK | TPMT 2579/4885CA12 2616/4885CA1 2942/4885 |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | GBA1, GAA, GBA2 | TPMT 131/4885CA12 2724/4885CA1 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.